Treatment of Older Adults with Acute Myeloid Leukemia

Dear Colleagues,

Curative-intent treatment algorithms with multi-agent chemotherapy and, often, hematopoietic cell transplantation are well-established for children, adolescents, and younger adults with acute myeloid leukemia (AML). However, with a median age of close to 70 years at diagnosis, AML primarily affects older adults. In these individuals, it is much less clear which treatment strategy optimizes the quantity and/or quality of life. Particular challenges the clinician faces in this patient population include increased therapeutic resistance and reduced tolerance to intensive therapies, especially when co-morbidities are present. The presumption that risks are not commensurate with potential benefits may explain why a large portion of older adults with AML never receives disease-directed therapy—despite data indicating that outcomes are improved if essentially all of these patients are given AML therapy. This Special Issue will focus on various aspects of the care of older adults with AML, including the decision-making process regarding most appropriate therapy (e.g., assessment of the fitness for AML therapy, determination of treatment intensity, and choice of “investigational” versus “standard” treatment), available and emerging intensive and non-intensive chemotherapy and transplant options, approaches to monitor treatment effects over time, quality of life considerations, and supportive care demands.

 

Dr. Roland B. Walter
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.